Pfizer’s lung cancer drug gets FDA approval

FILE PHOTO - The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S., August 1, 2016. REUTERS/Andrew Kelly/File Photo

(Reuters) – Pfizer Inc said on Thursday that its once-daily oral drug to treat a rare form of lung cancer received approval from the U.S. Food and Drug Administration. The drug, Vizimpro, will look to treat previously untreated patients with a form of metastatic non-small cell lung cancer (NSCLC). As the leading cause of cancer […]

Continue reading this article with a Fiji Times online membership.

More Stories